Searched for
SUBCUTANEOUS INJECTION
Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in CanadaDr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providin...- Roche brings 7-minute lung cancer shot to IndiaRoche Pharma India introduces a new injectable immunotherapy for lung cancer. This treatment takes only seven minutes, a significant reduct...
- Roche Pharma launches India’s first 7-minute injectable immunotherapy for lung cancerRoche Pharma has introduced Tecentriq, India's first under-the-skin immunotherapy for lung cancer. This new injection takes about seven min...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Biocon rolls out two biosimilars in US marketBiocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They...
- Alkem Laboratories launches semaglutide in India at Rs 450 per week, eyes booming weight-loss marketAlkem Laboratories has launched a new semaglutide injection in India. This drug targets the growing diabetes and weight loss market. It is ...
- Dr. Reddy’s Lab launches India’s first DCGI-approved Semaglutide injection for Type 2 DiabetesDr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian company to rece...
- Lupin gets USFDA nod for biosimilar drugLupin gets USFDA approval for Armlupeg, a biosimilar to Neulasta, to treat neutropenia in cancer patients. The drug will be manufactured at...
- Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IVBiocon Biologics has made strides in the healthcare sector by obtaining Health Canada’s approval for Yesintek and Yesintek IV, its latest a...
- India clears Roche’s 7-minute cancer injection Tecentriq for patients, with Phase IV trial conditionRoche has received clearance to import and market Atezolizumab injection (Tecentriq) for subcutaneous administration in India, potentially ...
- Biocon Biologics gets USFDA nod for diabetes medicationBiocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It...
- Dr Reddy's unit ties up with Shanghai Henlius BiotechDr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the cancer drug Dar...
- Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in JapanAdalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylos...
- US FDA approves J&J's blood cancer therapyJohnson & Johnson said on Thursday the U.S. Food and Drug Administration had approved its antibody-based therapy for patients with a diffic...
- Sun Pharma arm launches plaque psoriasis treatment drug in JapanIn a regulatory filing, Sun Pharmaceutical Industries said its "wholly-owned Japanese subsidiary has launched Ilumya Subcutaneous Injection...
- Decoding the impact of Ilumya, Sun Pharma's first biologic drug approved by the US FDALast year Sun Pharma signed another deal with South Korea's Samsung Biologics to get the drug manufactured on approval.
- Jubilant Life gets nod for Sodium Chloride injection“This is the first ANDA approval in injectables received by the company. We have filed two injectables and one ophthalmic product as on Mar...
- Dr Reddy’s Laboratories hits 52-week high on Sumatriptan launch in the USDRL pared some of the gains but was still trading 0.7% higher at Rs 2794.50. It has hit a low of Rs 2785.90 and a 52-week high of Rs 2823 o...
- Dr Reddy's launches autoinjector system in USPharma major Dr Reddy's Laboratories (DRL) said it has launched Sumatriptan Injection USP in the US.
- Fondaparinux injection issue resolved with USFDA: Dr Reddy's LaboratoriesDr Reddy's Labs has resolved all issues raised by a division of US health regulator over its promotional material for an anti-coagulant inj...
Load More
